Ihara H, Yabumoto H, Shima H, Mori Y, Ikoma F
Department of Urology, Hyogo College of Medicine, Nishinomiya, Japan.
Int Urol Nephrol. 1993;25(6):571-6.
In order to reduce the rate of homologous blood transfusion, predeposit autologous blood transfusion has been introduced in 134 out of 266 patients undergoing transurethral resection of the prostate since February 1988. Nine (6.7%) out of 134 patients who deposited their own blood were also transfused with homologous blood. In contrast, the rate of homologous blood transfusion was 22.7% in 132 patients who did not deposit autologous blood. Overall homologous blood transfusion rate (14.7%) in the past 4.5 years has been much lower than in the previous 4 years (22.2% in 203 patients). In 6 patients in whom blood donation was performed concurrently with administration of recombinant human erythropoietin, decrease of haemoglobin level was significantly less than in those without rHuEPO. Predeposit autologous blood transfusion can reduce homologous blood transfusion rate. It is safe and easily performed, and more effective when combined with rHuEPO administration even in elderly patients undergoing TURP.
自1988年2月起，在266例接受经尿道前列腺切除术的患者中，有134例采用了预存式自体输血，以降低同源输血率。134例预存自身血液的患者中有9例（6.7%）也接受了同源输血。相比之下，132例未预存自体血液的患者同源输血率为22.7%。过去4.5年的总体同源输血率（14.7%）远低于前4年（203例患者中为22.2%）。在6例同时进行献血和使用重组人促红细胞生成素的患者中，血红蛋白水平的下降明显少于未使用重组人促红细胞生成素的患者。预存式自体输血可降低同源输血率。它安全且易于实施，即使在接受经尿道前列腺切除术的老年患者中，与使用重组人促红细胞生成素联合使用时也更有效。
